Nervous Disorder TRIZ Cases

A composition containing Platycodon grandiflorum and Citrus aurantium extracts treats stress diseases.

Selumetinib inhibits the ERK pathway to increase SMN protein levels and improve motor neuron survival.

Low pH IgG formulation with glycine prevents aggregate formation and chemical degradation during extended storage periods.

Segmented detection of Kv1-complex autoantibodies improves diagnostic accuracy without increasing method complexity.

Recombinant adeno-associated virus vectors deliver therapeutic genes to target tissues via specific serotypes.

Gene expression analysis of FGF2 and related markers replaces subjective clinical assessment, reducing misdiagnosis risks in major depression treatment.

GILZ analog peptides bind activated p65 to block inflammatory gene transcription, addressing side effects of broad anti-inflammatory therapies.

Measures cytokine mRNA expression in immunized T-cells to resolve reliability and complexity trade-offs in potency assays.

A targeted nerve block method identifies specific neural pathways to inhibit pain signals and restore motor function.

A twelve-component intravenous infusion activates the liver and circulatory system to eliminate heroin and morphine ingredients from the body.

Tissue-engineered nerve grafts use inducible promoters to control neurotrophic growth factor expression for spatial and temporal precision.

Tumor hypoxia educated macrophages induce a unique regenerative phenotype to promote motor recovery and neural tissue repair.

A BDNF fusion protein binds transferrin receptors to cross the blood-brain barrier via transcytosis.

Formula Ia compounds combined with other agents reduce opioid side effects while maintaining effective pain relief via synergistic receptor modulation.

FTY720 composition reduces alpha-synuclein levels and blocks aggregation, restoring PP2A activity to delay motor symptom progression.

Compound 1 inhibits cholesterol biosynthesis enzymes to promote oligodendrocyte differentiation and myelin formation.

Deuterated phenethylamine derivatives extend half-life via kinetic isotope effects, reducing interpatient variability caused by CYP polymorphism.

Optimizing antibody dosage and frequency maintains effective serum concentrations while avoiding peak levels that cause vasogenic edema.

Oral administration of animal plasma proteins addresses inadequate treatment options by improving short-term and long-term memory performance.

Fermented food compositions containing Lactobacillus paracasei CBA L74 metabolites block gliadin peptide entry across the intestinal mucosa.

miR-33 nucleic acids degrade TDP-43 transcripts, preventing aggregation and cytotoxicity in motor neurons.

Conjugating Y-shaped branched polyethylene glycol to interferon alpha-2b extends serum half-life and reduces dosing frequency for viral infections.

Osmotin peptide increases neuronal cell viability and reduces cytotoxicity, addressing the lack of specific treatments for complex neurological diseases.

Cation exchange resin isolates TGF-β from milk to treat chronic inflammatory diseases without significant side effects.

CD10+ placental stem cells modulate the immune system via paracrine signaling, reducing inflammation and disease progression without severe side effects.

Antibodies targeting the Exon-17 region of periostin isoforms neutralize cell adhesive activity.

Merges multiple drug classes to address individual disease profiles while reducing treatment complexity and side effects.

IL12p40 induces Stat3 phosphorylation in neural stem cells, resolving unclear molecular mechanisms while improving motor function recovery.

Single-chain CD40 receptor agonist proteins use flexible peptide linkers to connect three soluble domains, reducing aggregation and proteolytic degradation.

Mutant Nogo receptor polypeptides interfere with signaling pathways to promote axonal growth in central nervous system neurons.

A di-PEGylated butyrylcholinesterase conjugate extends enzyme circulation time through covalent polymer attachment.

Bolaamphiphilic vesicles traverse the blood-brain barrier to deliver drugs without invasive procedures or side effects.

Codon-optimized FIG4 genes and expression cassettes deliver therapeutic protein levels to treat Charcot-Marie-Tooth Neuropathy type 4 J.

Characterizing eleven polymorphic forms of Compound A resolves the contradiction between therapeutic efficacy and manufacturing complexity.

Garcinia mangostana and Cinnamomum tamala extracts combine to enhance nitric oxide synthesis, ATP content, and protein synthesis.

A hydrophilic biocompatible sustained-release material injectable into internal body cavities via a urinary catheter.

Creatine derivatives alleviate pain and itch in inflammatory conditions by reducing tissue distortions without relying on steroids.

Truncated erythropoietin peptides bind EPOR to protect neurons, avoiding cell proliferation side effects.

A modified adeno-associated virus capsid protein displays peptides on its surface to mediate targeted transduction.

Removing Cremophor EL eliminates hypersensitivity reactions while maintaining bioavailability through an isoosmolar, ethanol-free emulsion.

BAFF polypeptide enriches immunoregulatory plasma cells in the CNS, resolving inflammation without depleting protective B cell subsets.

Direct compression of micronized tolcapone with release retardants extends therapeutic plasma levels by slowing dissolution rates.

A neuron activator combining 6-methylsulfinylhexyl isothiocyanates with unsaturated fatty acids and polyphenols to promote dopamine production.

Composite cannabis extracts reduce neural degeneration by modulating intracellular calcium levels, avoiding side effects of pure NMDA antagonists.

Citrate buffer and polysorbate 80 prevent aggregation in liquid anti-rabies antibody formulations, maintaining biological activity under thermal stress.

A transdermal adhesive patch uses a local anesthetic to promote absorption of basic anti-inflammatory analgesics.

Formula I compounds stabilize cognitive function and reduce neurodegeneration by inhibiting amyloid fibril formation and enhancing remyelination.

Isolated promoter sequences enable precise activation and repression of therapeutic genes within viral vectors.